Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Kahl on the Potential for Frontline BTK Inhibitor Combinations in MCL

September 10th 2021

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas

September 3rd 2021

Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.

Dr. Wang on the Final Results of the ACE-LY-004 Trial in MCL

September 1st 2021

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Dr. Riedell on the Importance of Identifying Early Relapse High-Risk MCL

September 1st 2021

Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.

Emerging Options Open the Door to Optimized Treatment Opportunities in Hematologic Malignancies

September 1st 2021

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

Dr. Kumar on the Future Directions With Pirtobrutinib in MCL

August 19th 2021

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Real-World Data Suggest Unmet Need for Effective Post-BTK Inhibitor Options in MCL

August 18th 2021

For patients with mantle cell lymphoma who have progressed after treatment with a BTK inhibitor such as ibrutinib, there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal outcomes.

Dr. Kumar on Addressing Unmet Needs in Mantle Cell Lymphoma

August 17th 2021

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Dr. Martin on the Importance of Designing Clinical Trials for Real-World Utility in MCL

August 16th 2021

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Acalabrutinib Demonstrates Long-Term Activity in Relapsed/Refractory MCL

August 14th 2021

Acalabrutinib monotherapy continued to be highly active and safe in patients with relapsed/refractory mantle cell lymphoma with longer-term follow-up.

Dr. Kumar on Navigating CAR T-Cell Therapy–Related Toxicities in MCL

August 13th 2021

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL

August 11th 2021

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Dr. Park on Selecting Among Available CAR T-Cell Therapies in MCL

August 5th 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Dr. Kumar on the Clinical Implications of the AIM Study in Mantle Cell Lymphoma

August 4th 2021

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma.

Dr. Kumar on Patient Considerations for Treatment in Relapsed/Refractory MCL

August 3rd 2021

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

Dr. Phillips on the Future of CAR T-Cell Therapy in MCL

August 2nd 2021

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCL

July 26th 2021

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Zanubrutinib Approved in Canada for MCL

July 26th 2021

Health Canada has approved the BTK inhibitor zanubrutinib for use in the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 therapy.

Venetoclax Plus Lenalidomide/Rituximab Elicits High Response Rates in Newly Diagnosed MCL

July 22nd 2021

The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.

Addition of Bortezomib to Bendamustine/Rituximab Induction Therapy Does Not Significantly Improve PFS in MCL

July 21st 2021

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.